View Takeda Pharmaceutical Co TAK investment & stock information. US Stock Market Stock Forecast US Share Price Predictions with Smart Prognosis Chart - 2020-2021 You can find here the Best USA Stocks to buy! TAK's 55 means that it ranks higher than 55% of stocks. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. Takeda Pharmaceutical Ltd's revenue in 2020 is $3,291,188,000,000.On average, 1 Wall Street analysts forecast TAK's revenue for 2021 to be $51,996,902,779,578, with the lowest TAK revenue forecast at $51,996,902,779,578, and the highest TAK revenue forecast at $51,996,902,779,578. The average Takeda Pharmaceutical Ltd stock price prediction forecasts a potential upside of 52.36% from the current TAK share price of $16.89. Showing 1-100 of 21,036 items.

Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. US Stock Forecast . Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. In 2022, TAK is forecast to generate $52,341,751,417,450 in revenue, with the lowest revenue forecast at $52,341,751,417,450 and the highest revenue forecast at $52,341,751,417,450. Takeda Pharmaceutical Ltd's earnings in 2020 is $44,241,000,000.On average, 1 Wall Street analysts forecast TAK's earnings for 2021 to be $3,518,004,848, with the lowest TAK earnings forecast at $3,518,004,848, and the highest TAK earnings forecast at $3,518,004,848.

What this means: Takeda Pharmaceutical Co. Ltd (TAK) gets an Overall Rank of 70, which is an above average rank under InvestorsObserver's stock ranking system. What this means: Takeda Pharmaceutical CO Ltd (TAK) gets an Overall Rank of 55, which is an above average rank under InvestorsObserver's stock ranking system. TAK Stock Analysis Overview . The consensus among 3 Wall Street analysts covering (NYSE: TAK) stock is to Strong Buy TAK stock. On average, Wall Street analysts predict that Takeda Pharmaceutical Ltd's share price could reach $25.73 by Sep 14, 2021. What is TAK's forecast return on assets (ROA) for 2021-2022? Copyright © 2018. (NYSE: TAK) Takeda Pharmaceutical Ltd's forecast annual revenue growth rate of -90.28% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of -16.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 3.25%. All Rights Reserved. Forecast Range Filter. See TAK stock predictions by 5 financial experts and find out if their Takeda Pharmaceutical Company stock forecast (TAK) is more bullish in comparison to other stocks in the Healthcare sector. Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 70% of revenue. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Who this matters to: Overall Ranking is a comprehensive evaluation. Stock Price data may be delayed up to 15 minutes. Portfolio results are unaudited and based on varying investment expiration dates. Find real-time TK - Teekay Corp stock quotes, company profile, news and forecasts from CNN Business. TAK's Return on Equity is forecast to be low in 2 years (0.08%); analysts are not confident in the firm's ability to efficiently generate return on equity, TAK is forecast to generate lower Return on Assets (0.03%) than the US Drug Manufacturers - Specialty & Generic industry average (7.37%), TAK's earnings are forecast to grow at a rate of -60.47% per year, which is not exceptional, TAK's revenue is forecast to grow at a rate of -90.28% per year, which is not exceptional, TAK's earnings are forecast to grow slower (-60.47% per year) than the US Drug Manufacturers - Specialty & Generic industry average (56.81%), TAK's earnings are forecast to grow slower (-60.47% per year) than the US market average (15.25%), TAK's revenues are forecast to grow slower (-90.28% per year) than the US Drug Manufacturers - Specialty & Generic industry average (-16.89%), TAK's revenues are forecast to grow slower (-90.28% per year) than the US market average (3.25%). What is TAK's earnings growth forecast for 2021-2022? What this means: Takeda Pharmaceutical CO Ltd (TAK) gets an Overall Rank of 56, which is an above average rank under InvestorsObserver's stock ranking system. Is Takeda Pharmaceutical Ltd Stock a good buy in 2020, according to Wall Street analysts? Price target in 14 days: 477.093 USD. What this means: Takeda Pharmaceutical CO Ltd (TAK) gets an Overall Rank of 55, which is an above average rank under InvestorsObserver's stock ranking system. Out of 3 analysts, 2 (66.67%) are recommending TAK as a Strong Buy, 0 (0.00%) are recommending TAK as a Buy, 1 (33.33%) are recommending TAK as a Hold, 0 (0.00%) are recommending TAK as a Sell, and 0 (0.00%) are recommending TAK as a Strong Sell. Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. From % To % Filter Reset / Default. TAK's 55 means that it ranks higher than 55% of stocks. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Takeda Pharmaceutical Co Ltd is Japan's largest pharmaceutical company, with revenue of JPY 3.3 trillion in 2019. Stock Price data may be delayed up to 15 minutes.

Portfolio results are unaudited and based on varying investment expiration dates. Get the latest Takeda Pharmaceutical Co TAK detailed stock quotes, stock data, Real-Time ECN, charts, stats and … Terms of Service | Privacy Policy. Who this matters to: Overall Ranking is a comprehensive evaluation. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. It considers technical and fundamental factors and is a good starting point for evaluating a stock. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Information is provided 'as-is' and solely for info Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. In 2022, TAK is forecast to generate $3,736,828,116 in earnings, with the lowest earnings forecast at $3,736,828,116 and the highest earnings forecast at $3,736,828,116.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. It considers technical and fundamental factors and is a good starting point for evaluating a stock. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. What is TAK's forecast return on equity (ROE) for 2021-2022? What is TAK's revenue growth forecast for 2021-2022? The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 70% of revenue. Copyright © 2018. TAK Stock Analysis Overview . Tesla Stock Price Forecast, TSLA stock price prediction. All Rights Reserved. What is TAK's Earnings Per Share (EPS) forecast for 2021-2022? Takeda Pharmaceutical Co Ltd is Japan's largest pharmaceutical company, with revenue of JPY 3.3 trillion in 2019. According to 3 Wall Street analysts that have issued a 1 year TAK price target, the average TAK price target is $25.73, with the highest TAK stock price forecast at $30.00 and the lowest TAK stock price forecast at $21.00. Terms of Service | Privacy Policy. (NYSE: TAK) Takeda Pharmaceutical Ltd's forecast annual earnings growth rate of -60.47% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 56.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%. Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116.